Want to see SRTA full AI Analyst Report?
Top Page
Strata Critical Medical
(NASDAQ:SRTA)
Select Model
Select Model
Rating:64Neutral
Price Target:
$5.00
▼(-19.22% Downside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by improving financial results and a very strong, low-leverage balance sheet, supported by a constructive earnings call with raised guidance and recent cash generation. These positives are tempered by weak cash-flow history in the provided financial statements, mixed technical momentum, and a weak valuation signal from a negative P/E with no dividend yield.
Positive Factors
Strong Revenue Growth
Sharp revenue growth indicates expanding demand and improved commercial traction, especially after the prior-year decline. If sustained, greater scale can support operating leverage, strengthen the company’s market position, and provide a broader base for future earnings growth.
Negative Factors
Persistent Negative Cash Flow
The long history of negative operating and free cash flow indicates that reported profits have not consistently converted into cash. Until cash generation improves sustainably, Strata may need balance-sheet resources to fund operations and investment, limiting financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Sharp revenue growth indicates expanding demand and improved commercial traction, especially after the prior-year decline. If sustained, greater scale can support operating leverage, strengthen the company’s market position, and provide a broader base for future earnings growth.
Read all positive factors
Strata Critical Medical (SRTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$418.45M
Dividend YieldN/A
Average Volume (3M)788.71K
Price to Earnings (P/E)9.5
Beta (1Y)2.16
Revenue Growth0.64%
EPS Growth19.57%
CountryUS
Employees327
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.24
Shares Outstanding88,466,805
10 Day Avg. Volume845,210
30 Day Avg. Volume788,712
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.42
Price to Sales (P/S)2.01
P/FCF Ratio-6.62
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue1.70
Enterprise Value/Gross Profit8.28
Enterprise Value/Ebitda-46.55
Forecast
1Y Price Target
$9.50Price Target Upside53.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$276.93M
Strata Critical Medical Business Overview & Revenue Model
Company Description
Strata Critical Medical, Inc. is dedicated to supporting healthcare providers throughout the United States by offering swift logistical management and specialized medical assistance. A significant part of their operations involves the movement of ...
Strata Critical Medical Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Positive
The call presents a largely positive picture driven by robust clinical growth, accretive bolt-on acquisitions, stronger-than-expected revenue and raised full-year guidance, and consecutive quarters of cash generation. These positives are tempered by near-term softness in Logistics (a ~3% revenue headwind from one customer), margin pressure from fuel pass-through mechanics and maintenance, and working-capital/transaction-related cash drag. Management provided concrete mitigation plans for Logistics margins and expects recovery in the back half of the year, supporting a constructive outlook.Positive Updates
Strong Quarterly and YoY Revenue Growth
Total revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 versus $45.1 million in Q2 2025.
Negative Updates
Logistics Revenue Softness
Logistics year-over-year revenue growth moderated to 6.9%; Logistics revenue increased only ~1% sequentially versus Q1 2026, below expectations.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Quarterly and YoY Revenue Growth
Total revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 versus $45.1 million in Q2 2025.
Read all positive updates
Company Guidance
Strata raised 2026 revenue guidance to $285–$295 million (from $260–$275M) and adjusted EBITDA to $33–$35 million (from $29–$33M); on a pro forma basis assuming recent clinical deals closed Jan 1, 2026, revenue would be $295–$305M and adjusted EBITDA $36–$38M. They still expect free cash flow before aircraft acquisitions of $15–$22M in 2026, plan for the $17.5M Joby earn‑out to be received by year‑end, and see adjusted SG&A running in the low $9M range for the balance of the year. Segment outlook: Logistics revenue is expected to decline high single digits sequentially in Q3 (including an approximate 3% revenue headwind from one nonexclusive customer) with Logistics gross margin recovering to 18.5%–20% in H2 and a target of ~20% for 2027; Clinical revenue is expected to grow ~20% Q2→Q3 and mid‑single digits Q3→Q4, with Clinical gross margins rising to ~27%–28% in H2 (mix driving Clinical to roughly 40% of H2 revenue and ~50% of H2 gross profit).Strata Critical Medical Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
86
Very Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 255.97M | 197.14M | 248.69M | 225.18M | 146.12M | 50.53M |
| Gross Profit | 52.62M | 41.13M | 58.92M | 42.12M | 22.27M | 10.52M |
| EBITDA | -9.36M | -5.71M | -21.60M | -50.43M | -22.31M | -43.10M |
| Net Income | 40.22M | 41.35M | -27.31M | -56.08M | -27.26M | -40.05M |
Balance Sheet | ||||||
| Total Assets | 332.70M | 325.47M | 256.68M | 294.94M | 325.02M | 335.88M |
| Cash, Cash Equivalents and Short-Term Investments | 22.75M | 61.23M | 127.14M | 166.14M | 192.08M | 281.97M |
| Total Debt | 4.25M | 3.31M | 9.32M | 24.52M | 18.33M | 716.00K |
| Total Liabilities | 53.38M | 46.40M | 34.74M | 60.64M | 50.54M | 44.51M |
| Stockholders Equity | 279.32M | 279.07M | 221.94M | 234.30M | 274.49M | 291.37M |
Cash Flow | ||||||
| Free Cash Flow | -43.70M | -59.92M | -35.51M | -34.46M | -37.86M | -15.91M |
| Operating Cash Flow | -30.90M | -48.91M | -2.52M | -32.35M | -37.13M | -15.62M |
| Investing Cash Flow | 1.51M | 69.75M | -1.02M | 17.09M | 79.34M | -321.34M |
| Financing Cash Flow | -13.73M | -8.91M | -5.76M | -76.00K | -1.08M | 332.26M |
Strata Critical Medical Technical Analysis
Negative
6.19
Price Trends
5.50
Negative
5.53
Negative
5.17
Negative
Market Momentum
-0.16
Positive
30.05
Neutral
8.97
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTA, the sentiment is Negative. The current price of 6.19 is above the 20-day moving average (MA) of 5.23, above the 50-day MA of 5.50, and above the 200-day MA of 5.17, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 30.05 is Neutral, neither overbought nor oversold. The STOCH value of 8.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRTA.
Strata Critical Medical Risk Analysis
Strata Critical Medical disclosed 57 risk factors in its most recent earnings report. Strata Critical Medical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Strata Critical Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $418.45M | 9.47 | 14.27% | ― | 0.64% | 19.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $240.54M | -97.86 | -0.54% | ― | -13.38% | -155.45% | |
50 Neutral | $120.18M | -0.45 | 182.56% | ― | 3.14% | 48.61% | |
46 Neutral | $127.60M | -1.56 | 7.78% | 2.36% | 16.15% | 32.19% |
* Healthcare Sector Average
SRTA
Strata Critical Medical
4.73
-0.48
-9.21%
ASLE
AerSale Corporation
5.04
-3.20
-38.83%
FLYX
flyExclusive
1.25
-3.10
-71.26%
SRFM
Surf Air Mobility, Inc.
0.97
-4.17
-81.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.